LAUSR

BACKGROUND Secukinumab is a first-in-class IL-17A monoclonal antibody that has demonstrated an excellent safety and efficacy profile in Phase III studies. OBJECTIVES To evaluate the effectiveness of secukinumab in daily clinical practice and to understand the clinical and epidemiological characteristics of patients treated with secukinumab in clinical settings. METHODS This multi-center prospective observational study recruited adult patients with moderate-to-severe plaque psoriasis from 12 Spanish hospitals between January and December 2016. These patients were treated with secukinumab and prospectively followed at 12-week intervals for 52 weeks. RESULTS In total, 158 patients were recruited to the study. Psoriasis Area and Severity Index (PASI)-75 achiever rates were 57%, 83.5%, 89%, and 78.5% at weeks 4, 12, 24, and 52, respectively. PASI-90 achiever rates were 27.8%, 62%, 64.6%, and 63.2% at weeks 4, 12, 24, and 52, respectively. PASI-75 and -90 responders were significantly higher more common among patients with body mass index (BMI) under 30 and patients without previous failure to other biologic therapies. LIMITATIONS Observational study. Psoriasis time-from-onset was not evaluated. CONCLUSIONS Secukinumab is an effective and safe treatment with effectiveness rates similar to those found in its Phase III studies. These rates endure up to a year from start of treatment.